Krassimira Olegova Todorova

Prof. Dr. Krassimira Olegova Todorova


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Eytan Eobert BarneaEytan Eobert Barnea
Eytan Eobert Barnea
DLDavid M. Lubman
David M. Lubman
YLYan-Hui Liu
Yan-Hui Liu
VAVictor Absalon-Medina
Victor Absalon-Medina
SHSoren Bohos Hayrabedyan
Soren Bohos Hayrabedyan
TBTimothy J. Barder
Timothy J. Barder
Endogenous PIF, upon which embryo development is dependent, is secreted only by viable mammalian embryos, and absent in non-viable ones. Synthetic PIF (sPIF) administration promotes singly cultured embryos development and protects against their demise caused by embryo-toxic serum. To identify and characterize critical sPIF-embryo protein interactions novel biochemical and bio-analytical methods were specifically devised. FITC-PIF uptake/binding by cultured murine and equine embryos was examined and compared with scrambled FITC-PIF (control). Murine embryo (d10) lysates were fractionated by reversed-phase HPLC, fractions printed onto microarray slides and probed with Biotin-PIF, IDE and Kv1.3 antibodies, using fluorescence detection. sPIF-based affinity column was developed to extract and identify PIF-protein interactions from lysates using peptide mass spectrometry (LC/MS/MS). In silico evaluation examined binding of PIF to critical targets, using mutation analysis. PIF directly targets viable cultured embryos as compared with control peptide, which failed to bind. Multistep Biotin-PIF targets were confirmed by single-step PIF-affinity column based isolation. PIF binds protein disulfide isomerases a prolyl-4-hydroxylase β-subunit, (PDI, PDIA4, PDIA6-like) containing the antioxidant thioredoxin domain. PIF also binds protective heat shock proteins (70&90), co-chaperone, BAG-3. Remarkably, PIF targets a common RIPK site in PDI and HSP proteins. Further, single PIF amino acid mutation significantly reduced peptide-protein target bonding. PIF binds promiscuous tubulins, neuron backbones and ACTA-1,2 visceral proteins. Significant anti-IDE, while limited anti-Kv1.3b antibody-binding to Biotin-PIF positive lysates HPLC fractions were documented. Collectively, data identifies PIF shared targets on PDI and HSP in the embryo. Such are known to play a critical role in protecting against oxidative stress and protein misfolding. PIF-affinity-column is a novel utilitarian method for small molecule targets direct identification. Data reveals and completes the understanding of mechanisms involved in PIF-induced autotrophic and protective effects on the embryo.

18 July 2021 in Genes
Verified
Journal Article
Open access
PDF file
Nikolay MehterovNikolay Mehterov
Nikolay Mehterov
MKMaria Hristova Kazakova
Maria Hristova Kazakova
YSYordan Sbirkov
Yordan Sbirkov
BVBoyan Vladimirov
Boyan Vladimirov
NBNikolay Belev
Nikolay Belev
VSVictoria Sarafian
Victoria Sarafian
Almost all transcribed human genes undergo alternative RNA splicing, which increases the diversity of the coding and non-coding cellular landscape. The resultant gene products might have distinctly different and, in some cases, even opposite functions. Therefore, the abnormal regulation of alternative splicing plays a crucial role in malignant transformation, development, and progression, a fact supported by the distinct splicing profiles identified in both healthy and tumor cells. Drug resistance, resulting in treatment failure, still remains a major challenge for current cancer therapy. Furthermore, tumor cells often take advantage of aberrant RNA splicing to overcome the toxicity of the administered chemotherapeutic agents. Thus, deciphering the alternative RNA splicing variants in tumor cells would provide opportunities for designing novel therapeutics combating cancer more efficiently. In the present review, we provide a comprehensive outline of the recent findings in alternative splicing in the most common neoplasms, including lung, breast, prostate, head and neck, glioma, colon, and blood malignancies. Molecular mechanisms developed by cancer cells to promote oncogenesis as well as to evade anticancer drug treatment and the subsequent chemotherapy failure are also discussed. Taken together, these findings offer novel opportunities for future studies and the development of targeted therapy for cancer-specific splicing variants.

1 July 2015 in Immunobiology
Verified
Journal Article
Closed access
Eytan Eobert BarneaEytan Eobert Barnea
Eytan Eobert Barnea
DKDavid Kirk
David Kirk
KTKrassimira Todorova
Krassimira Todorova
JMJames McElhinney
James McElhinney
SHSoren Bohos Hayrabedyan
Soren Bohos Hayrabedyan
NFNelson Fernández
Nelson Fernández

24 April 2012 in American Journal of Reproductive Immunology
Verified
Journal Article
Closed access
PDF file
SHSoren Bohos Hayrabedyan
Soren Bohos Hayrabedyan
KTKrassimira Todorova
Krassimira Todorova
SPShina Pashova
Shina Pashova
MMMargarita Mollova
Margarita Mollova
NFNelson Fernández
Nelson Fernández

Verified
Journal Article
Open access
PDF file
TITsvetomira Ivanova
Tsvetomira Ivanova
YMYuliia Mariienko
Yuliia Mariienko
Nikolay MehterovNikolay Mehterov
Nikolay Mehterov
MKMaria Hristova Kazakova
Maria Hristova Kazakova
YSYordan Sbirkov
Yordan Sbirkov
VSVictoria Sarafian
Victoria Sarafian
At present it is well-defined that autophagy is a fundamental process essential for cell life but its pro-viral and anti-viral role has been stated out with the COVID pandemic. However, viruses in turn have evolved diverse adaptive strategies to cope with autophagy driven host defense, either by blocking or hijacking the autophagy machinery for their own benefit. The mechanisms underlying autophagy modulation are presented in the current review which summarizes the accumulated knowledge on the crosstalk between autophagy and viral infections, with a particular emphasizes on SARS-CoV-2. The different types of autophagy related to infections and their molecular mechanisms are focused in the context of inflammation. In particular, SARS-CoV-2 entry, replication and disease pathogenesis are discussed. Models to study autophagy and to formulate novel treatment approaches and pharmacological modulation to fight COVID-19 are debated. The SARS-CoV-2—autophagy interplay is presented, revealing the complex dynamics and the molecular machinery of autophagy. The new molecular targets and strategies to treat COVID-19 effectively are envisaged. In conclusion, our finding underline the importance of development new treatment strategies and pharmacological modulation of autophagy to fight COVID-19.

15 December 2006 in Journal of Molecular Histology
Verified
Journal Article
Closed access
PDF file
MKM. Karaivanov
M. Karaivanov
KTKrassimira Todorova
Krassimira Todorova
AKA. Kuzmanov
A. Kuzmanov
SHSoren Bohos Hayrabedyan
Soren Bohos Hayrabedyan